Dataset_ID	Sample_ID	Platform_ID	age	biopsy_date_mmddyy	bmn_grade	er_status	er_percent_positive	her_2_fish	her_2_ihc	her_2_status	histology	pcr_or_rd	post_chemo_ln_total	post_chemo_size_cm	pr_status	pr_percent_positive	prechemo_n	prechemo_t	preoperative_treatment	race	randomized_1_fac_2_t_fac	surgery_date	surgery_type	treatment_received_1_fac_2_t_fac
GSE20271	GSM508012	GPL96	48	11-11-05	3	N	0	ND	0	N	Infiltrating Ductal Carcinoma	pCR	0/12	0	N	0	2	2	FEC x(6 )	W	1	5-16-06	Lumpectomy	1
GSE20271	GSM508013	GPL96	55	11-4-06	2	P	3+	ND	1	N	Infiltrating Ductal Carcinoma	RD	1/10	1.2	P	2+	0	3	FEC x(6 )	W	1	9-9-06	Lumpectomy	1
GSE20271	GSM508014	GPL96	45	1-30-06	3	N	0	ND	3	P	infiltrating Ductal Carcinoma	RD	0/24	2.1	N	0	0	2	FEC x(6 )	W	1	6-26-06	Lumpectomy	1
GSE20271	GSM508015	GPL96	39	2-1-06	2	P	2+	ND	0	N	Infiltrating Ductal Carcinoma	RD	1/13	0.3	N	0	2	2	FEC x(6 )	W	1	5-24-06	Mastectomy	1
GSE20271	GSM508016	GPL96	49	2-13-06	1	P	25-50	ND	1	N	Infiltrating Ductal Carcinoma	RD	0/18	1	N	0	0	1	FEC x(6 )	W	1	7-27-06	Mastectomy	1
GSE20271	GSM508017	GPL96	39	2-13-06	2	N	0	positive	3	P	Infiltrating Ductal Carcinoma	RD	0/13	2	N	0	1	3	FEC x(6 )	W	1	7-26-06	Mastectomy	1
GSE20271	GSM508018	GPL96	48	12-20-05	3	N	0	ND	3	P	Infiltrating Ductal Carcinoma	RD	1/10	2.3	P	75	1	NA	FECx(6)	W	1	5-24-06	Mastectomy	1
GSE20271	GSM508019	GPL96	73	9-23-05	3	N	0	ND	0	N	Infiltrating Ductal Carcinoma	RD	1/16	3.4	P	60	0	3	FEC x(6 )	W	1	2-20-06	Mastectomy	1
GSE20271	GSM508020	GPL96	42	1-13-06	2	P	100	ND	0	N	infiltrating Mucosecretor Carcinoma	RD	2/7	4	P	90	1	3	FEC x(5 ) due to NC +Paclitaxel x (7)	W	1	6-19-06	Mastectomy	1
GSE20271	GSM508021	GPL96	42	2-16-06	3	P	75	ND	1	N	Infiltrating Ductal Carcinoma	RD	11/14	8	P	99	1	2	FEC x(6 )	H	1	7-21-06	Mastectomy	1
GSE20271	GSM508022	GPL96	45	6-4-06	3	N	2+	ND	0	N	Infiltrating Lobular Carcinoma	RD	3/15	8	N	0	1	3	FEC x(6 )	W	1	6-4-06	Mastectomy	1
GSE20271	GSM508023	GPL96	62	2-27-06	2	P	100	ND	0	N	Mixed; Ductal and Lobular	RD	5/12	Not medible	P	90	0	3	FEC x( 6)	W	1	7-31-06	Mastectomy	1
GSE20271	GSM508024	GPL96	46	2-2-05	NA	P	90	NA	NA	N	IDC	RD	4/25	1	P	90	1	4	FAC  x 6  (Taxol x 12 post Sx)	H	1	7-26-05	MRM	1
GSE20271	GSM508025	GPL96	50	3-15-06	3	N	0	1.1	NA	N	IDC	RD	6/9	1.5	N	0	1	1	FEC x 6	W	1	9-8-06	MRM	1
GSE20271	GSM508026	GPL96	55	4-2-04	2	P	50	0	NA	N	IDC	RD	8/43	2	P	10	1	2	FEC x 6	W	1	10-7-04	MRM	1
GSE20271	GSM508027	GPL96	46	4-11-06	1	P	91	1.25	1	N	IDC	RD	6/13	2	P	100	3	2	FEC x 6 (P.D “new supra & infraclavicular Ln”)Taxol x 12	W	1	12-8-06	MRM	1
GSE20271	GSM508028	GPL96	45	11-19-03	1	P	95	1.65	1	N	IDC	RD	3/11	3	P	80	1	1	FEC x 6	W	1	5-26-04	MRM	1
GSE20271	GSM508029	GPL96	73	7-27-04	3	N	0	10.81	3	P	IDC	RD	0/16	3.3	N	0	0	2	FEC x 6	W	1	12-16-04	MRM	1
GSE20271	GSM508030	GPL96	50	2-20-04	2	P	50	1.66	2	N	IDC	RD	10/12	3.5	P	50	0	4	FAC x 6	W	1	8-17-04	MRM	1
GSE20271	GSM508031	GPL96	50	3-30-04	2	P	100	1.08	NA	N	IDC	RD	7/17	3.8	P	20	3	2	FEC x 6	W	1	9-16-04	MRM	1
GSE20271	GSM508032	GPL96	64	9-3-04	2	P	80	1.02	NA	N	IDC	RD	10/31	4	P	10	0	2	FAC x 6	W	1	2-16-05	MRM	1
GSE20271	GSM508033	GPL96	43	1-21-05	NA	P	75	NA	2	N	IDC	RD	0/5	residual cancer	P	70	1	4	FAC  x 6	H	1	8-20-05	MRM	1
GSE20271	GSM508034	GPL96	43	7-13-05	3	P	70	NA	NA	N	IDC	RD	0/0	residual cancer	P	90	1	4	FAC  x 6	H	1	1-28-06	MRM	1
GSE20271	GSM508035	GPL96	58	9-8-04	2	N	0	NA	0	N	IDC	pCR	0/14	0	N	0	1	2	FAC x 6 Taxol x 4	H	1	4-1-05	MRM/ALND	1
GSE20271	GSM508036	GPL96	43	9-16-05	NA	P	90	NA	NA	N	IDC	pCR	0/8	0	N	5	2	4	FAC x 6  (Taxol post Sx)	H	1	3-7-06	MRM/ALND	1
GSE20271	GSM508037	GPL96	44	11-30-05	NA	P	95	NA	NA	N	IDC	pCR	0/14	0	P	90	2	2	FAC x 6  (Taxol post Sx)	H	1	6-6-06	MRM/ALND	1
GSE20271	GSM508038	GPL96	46	9-23-05	NA	P	30	NA	NA	N	IDC	pCR	0/6	0	P	30	2	4	FAC x 6	H	1	3-21-06	MRM/ALND	1
GSE20271	GSM508039	GPL96	32	8-30-05	3	P	90	NA	0	N	IDC	RD	0/36	1	N	0	2	2	FAC x 6 (Last Cycle only AC  no 5-FU)	W	1	2-2-06	MRM/ALND	1
GSE20271	GSM508040	GPL96	54	5-13-05	2	N	0	4.7	3	P	IDC	RD	27/28	1.9	N	0	2	4	FEC x 6	W	1	2-20-06	MRM/ALND	1
GSE20271	GSM508041	GPL96	66	1-13-05	2	P	40	NA	1	N	IDC/ILC	RD	25/34	2.3	N	5	1	1	FAC x 6	W	1	7-27-05	MRM/ALND	1
GSE20271	GSM508042	GPL96	39	5-5-04	3	N	0	NA	0	N	IDC	RD	0/10	2.3	N	0	2	3	Taxol  x  6  FAC x  6	H	1	11-12-04	MRM/ALND	1
GSE20271	GSM508043	GPL96	58	4-12-05	3	N	0	1.04	NA	N	IDC	RD	9/16	5	N	0	2	4	FEC x 6	H	1	11-2-05	MRM/ALND	1
GSE20271	GSM508044	GPL96	52	9-23-05	2	P	60	NA	NA	N	IDC	RD	5/9	NA	P	70	1	4	FAC x 6  (Taxol x 12 post Sx)	H	1	3-16-06	MRM/ALND	1
GSE20271	GSM508045	GPL96	61	4-3-06	3	P	100	NA	1	N	IDC	RD	15/20	NA	P	90	2	3	FAC x 6  (Taxol post Sx)	H	1	11-21-06	MRM/ALND	1
GSE20271	GSM508046	GPL96	37	4-24-06	3	P	70	NA	NA	N	IDC	RD	6/23	NA	P	100	2	4	FAC x 6  (Taxol x 12 post Sx)	H	1	10-28-06	MRM/ALND	1
GSE20271	GSM508047	GPL96	40	10-12-05	3	N	NA	NA	NA	N	IDC	RD	3/11	NA	N	NA	0	4	FAC x 6  (Taxol x 11 post Sx)	H	1	4-11-06	MRM/ALND	1
GSE20271	GSM508048	GPL96	41	1-4-06	1	P	90	NA	NA	N	IDC	RD	6/19	NA	P	90	1	2	FAC x 6  (Taxol post Sx)	H	1	7-8-06	MRM/ALND	1
GSE20271	GSM508049	GPL96	42	12-14-05	3	N	NA	NA	NA	N	IDC	RD	8/12	NA	N	NA	1	4	FAC x 6  (Taxol x 12 post Sx)	H	1	5-27-06	MRM/ALND	1
GSE20271	GSM508050	GPL96	53	3-29-06	2	P	70	NA	NA	N	IDC	RD	1/18	NA	N	NA	2	4	FAC x 6  (Taxol x 12 post Sx)	H	1	10-12-06	MRM/ALND	1
GSE20271	GSM508051	GPL96	62	8-3-05	3	P	100	NA	NA	N	IDC	RD	0/17	residual cancer	P	90	2	4	FAC  x 6	H	1	1-26-06	MRM/ALND	1
GSE20271	GSM508052	GPL96	64	10-12-05	3	N	NA	NA	NA	N	IDC	RD	0/15	residual cancer	N	NA	0	3	FAC x 6  (Taxol post Sx)	H	1	3-18-06	MRM/ALND	1
GSE20271	GSM508053	GPL96	69	1-13-06	3	P	80	NA	NA	N	IDC	RD	0/21	residual cancer	P	80	1	4	FAC x 6  (Taxol x 12 post Sx)	H	1	8-1-06	MRM/ALND	1
GSE20271	GSM508054	GPL96	35	12-19-05	3	N	NA	NA	NA	N	IDC	RD	0/14	residual cancer	N	NA	1	3	FAC x 6  (Taxol x 12 post Sx)	H	1	6-23-06	MRM/ALND	1
GSE20271	GSM508055	GPL96	38	9-1-04	2	P	90	NA	NA	N	IDC	RD	0/24	residual cancer	P	70	1	2	FAC x 6  (Taxol x 12 post Sx)	H	1	2-21-05	MRM/ALND	1
GSE20271	GSM508056	GPL96	40	11-3-04	3	N	NA	NA	NA	N	IDC	RD	0/29	residual cancer	N	NA	1	3	FAC x 6   (Taxol x 10 post Sx)	H	1	7-12-05	MRM/ALND	1
GSE20271	GSM508057	GPL96	71	8-2-04	3	P	90	NA	NA	N	IDC	RD	0/26	residual cancer	P	10	1	4	FAC x 6   (Taxol x 12 post Sx)	H	1	3-15-05	MRM/ALND	1
GSE20271	GSM508058	GPL96	74	12-9-05	NA	N	NA	NA	NA	N	IDC	RD	0/12	residual cancer	N	NA	1	4	FAC x 6	H	1	6-24-06	MRM/ALND	1
GSE20271	GSM508059	GPL96	36	5-27-05	NA	P	70	NA	NA	N	IDC	RD	1/1	NA	P	70	0	3	FAC  x 6  (Taxol x 12 post Sx)	H	1	11-8-05	MRM/LNB	1
GSE20271	GSM508060	GPL96	52	8-26-05	2	N	0	NA	0	N	IDC	RD	21/24	NA	N	0	2	4	FEC x 6	H	1	4-28-06	NA	1
GSE20271	GSM508061	GPL96	42	8-31-05	NA	N	0	NA	0	N	IDC	RD	2/20	NA	P	NA	0	3	FEC x 6	H	1	3-9-06	NA	1
GSE20271	GSM508062	GPL96	45	6-16-05	2	P	0	NA	0	N	IDC	RD	11/17	NA	P	0	3	4	FEC x 6	H	1	1-5-06	NA	1
GSE20271	GSM508063	GPL96	57	8-10-04	NA	N	0	NA	0	N	IDC	RD	5/17	NA	N	0	1	3	FEC x 6	H	1	1-13-05	NA	1
GSE20271	GSM508064	GPL96	61	6-13-05	NA	N	0	NA	3	P	IDC	RD	0/13	residual cancer	N	0	0	2	FEC x 6	H	1	12-9-05	NA	1
GSE20271	GSM508065	GPL96	56	5-15-06	NA	P	95	NA	NA	N	IDC	RD	ND	ND	N	NA	2	4	FAC x 6	H	1	ND	ND	1
GSE20271	GSM508066	GPL96	34	6-13-05	NA	N	NA	NA	NA	N	IDC	RD	ND	ND	N	NA	1	4	FAC x 5(d/t P.D)	H	1	ND	ND	1
GSE20271	GSM508067	GPL96	49	9-24-04	3	P	NA	1.26	0	N	IDC/IBC	RD	ND	ND	P	NA	0	4	FAC x 4  (d/t P.D) Taxotere x 2 (d/t severe Dehydration) Xeloda x 2(d/t P.D) XRT+ Xeloda Taxol x 2	B	1	ND	ND	1
GSE20271	GSM508068	GPL96	68	10-3-05	NA	N	NA	NA	NA	N	IDC	RD	ND	ND	N	NA	2	4	FAC x 3 (D/T PD) Taxol x 4	H	1	ND	ND	1
GSE20271	GSM508069	GPL96	36	11-9-05	NA	N	NA	NA	NA	N	IDC	RD	ND	ND	N	NA	2	3	FAC x 4 (D/T P.D.)	H	1	ND	ND	1
GSE20271	GSM508070	GPL96	49	1-31-05	NA	P	30	NA	3	P	IDC	RD	ND	ND	N	NA	2	4	FAC  x 6	H	1	ND	ND for liver mets	1
GSE20271	GSM508071	GPL96	59	10-1-06	3	N	0	ND	0	N	Infiltrating Ductal Carcinoma	pCR	0/18	0	N	0	1	2	FEC x(6)	W	1	2-6-06	Quadrantectomy	1
GSE20271	GSM508072	GPL96	49	7-29-05	3	N	0	ND	3	P	Infiltrating Ductal Carcinoma	RD	1/14	1.5	N	0	0	2	FEC x( 6)	W	1	1-19-06	Quadrantectomy	1
GSE20271	GSM508073	GPL96	60	9-19-05	3	P	100	ND	0	N	Infiltrating Ductal Carcinoma	RD	0/13	1.7	P	60	0	2	FEC x(6 )	W	1	2-13-06	Quadrantectomy	1
GSE20271	GSM508074	GPL96	56	7-29-05	3	N	0	ND	0	N	Infiltrating Ductal Carcinoma	RD	0/18	1.8	N	0	0	3	FEC x(6 )	W	1	12-20-05	Quadrantectomy	1
GSE20271	GSM508075	GPL96	44	11-4-06	2	P	70	ND	1	N	Infiltrating Ductal Carcinoma	RD	1/14	2	P	90	1	2	FEC x( 6)	W	1	8-30-06	Quadrantectomy	1
GSE20271	GSM508076	GPL96	47	1-30-06	2	P	85	ND	1	N	Infiltrating Ductal Carcinoma	RD	0/18	2	P	95	0	2	FEC x(6 )	W	1	6-30-06	Quadrantectomy	1
GSE20271	GSM508077	GPL96	45	11-1-06	2	P	25-50	ND	0	N	Infiltrating Ductal Carcinoma	RD	1/7	2.5	P	25-50	NA	2	FEC x( 6)	W	1	7-26-06	Quadrantectomy	1
GSE20271	GSM508078	GPL96	59	7-2-06	3	P	80	8	3	P	Infiltrating Ductal Carcinoma	RD	0/19	3.2	P	2	0	2	FEC x(6 )	W	1	7-25-06	Quadrantectomy	1
GSE20271	GSM508079	GPL96	53	8-5-04	3	P	90	0.83	NA	N	IDC	RD	2/23	0	N	5	1	2	FAC x 6 (neo-adj)	W	1	1-5-05	SM/ALND	1
GSE20271	GSM508080	GPL96	46	7-6-05	3	N	0	0.77	NA	N	IDC	RD	0/18	0.8	N	0	2	2	FAC x 6	B	1	2-15-06	SM/ALND	1
GSE20271	GSM508081	GPL96	40	1-15-04	2	P	100	NA	0	N	IDC	RD	1/5	1.1	P	50	0	2	FAC x 6 (neo-adj); Taxol x 12 (adj); Tamoxifen	W	1	6-25-04	SM/ALND	1
GSE20271	GSM508082	GPL96	48	8-15-05	2	P	90	1.41	1	N	IDC	RD	4/10	2.1	P	75	1	2	FAC x 6	H	1	2-20-06	SM/ALND	1
GSE20271	GSM508083	GPL96	61	8-10-05	1	P	25	0.97	2	N	IDC	RD	0/7	2.3	P	10	0	2	FAC x 6	W	1	2-1-06	SM/ALND	1
GSE20271	GSM508084	GPL96	62	6-29-05	2	P	100	0.93	NA	N	IDC	RD	2/7	2.5	P	100	0	2	FAC x 5	H	1	1-11-06	SM/ALND	1
GSE20271	GSM508085	GPL96	46	4-7-05	3	N	0	0.87	1	N	IDC	RD	17/22	3	N	0	2	4	FEC x 6	B	1	9-30-05	SM/ALND	1
GSE20271	GSM508086	GPL96	47	6-9-06	2	N	95	NA	NA	P	IDC	RD	3/11	NA	N	95	1	3	FAC x 6  (Taxol x 6 post Sx - still under adj chemo)	H	1	12-9-06	SM/ALND	1
GSE20271	GSM508087	GPL96	59	8-16-05	3	N	0	NA	0	N	IDC	pCR	0/4	0	N	0	0	2	FAC x 4 (stopped after 4 of 6 planned cycles d/t nausea fatigue fever)	W	1	12-28-05	SM/LNB	1
GSE20271	GSM508088	GPL96	49	2-9-06	2	P	70	NA	0	N	IDC	RD	0/3	1	P	95	0	2	FEC x 5	W	1	6-30-06	SM/LNB	1
GSE20271	GSM508089	GPL96	38	2-1-06	3	N	0	NA	0	N	IDC	RD	2/28	1.3	N	0	1	2	FAC x 6	W	1	7-27-06	SM/LNB	1
GSE20271	GSM508090	GPL96	66	5-24-04	3	N	3	NA	0	N	IDC	RD	0/3	2	N	3	0	2	FAC x 6	W	1	11-22-04	SM/LNB	1
GSE20271	GSM508091	GPL96	31	12-23-04	3	N	0	1.04	2	N	IDC	RD	0/10	3	N	0	1	3	FAC x 6	H	1	6-22-05	SM/LNB	1
GSE20271	GSM508092	GPL96	44	7-8-04	3	P	90	NA	0	N	IDC	RD	2/24	0.5	P	10	2	0	FEC x 6	H	1	4-5-05	TM/ALND	1
GSE20271	GSM508093	GPL96	52	3-2-04	2	N	0	1.29	NA	N	IDC	RD	0/29	0.5	N	0	0	2	FEC x 6	W	1	8-3-04	TM/ALND	1
GSE20271	GSM508094	GPL96	43	1-12-05	2	P	20	1.17	1	N	IDC	RD	1/15	1.2	N	0	1	2	FAC x 6	W	1	7-13-05	TM/ALND	1
GSE20271	GSM508095	GPL96	34	1-12-06	2	P	90	1.74	1	N	IDC	RD	1/14	2.2	P	30	2	2	FAC x 6	H	1	6-9-06	TM/ALND	1
GSE20271	GSM508096	GPL96	48	2-27-06	2	N	5	NA	0	N	IDC	RD	0/18	1.4	N	2	1	2	FAC x 6	W	1	7-31-06	TM/LNB	1
GSE20271	GSM508097	GPL96	57	1-13-06	2	N	0	1.17	2	N	IDC	RD	0/1	2.2	N	0	0	2	FAC x 6	B	1	7-28-06	TM/LNB	1
GSE20271	GSM508098	GPL96	73	8-1-06	2	P	90	1.02	2	N	IDC	RD	1/2	3	N	0	0	4	FEC x  4 (original planned was 6 cycles disc. due to anorexia)	W	1	12-1-06	TM/LNB	1
GSE20271	GSM508099	GPL96	49	2-23-06	3	N	0	ND	3	P	Only Infiltrating	pCR	0/2	0	N	0	0	2	Paclitaxel x(12 )  + FEC x(4 )	W	2	12-9-06	Lumpectomy	2
GSE20271	GSM508100	GPL96	37	7-9-05	2	P	40	ND	0	N	Infiltrating Ductal Carcinoma	RD	0	1	P	80	0	2	Paclitaxel x(12 )  + FEC x(4 )	H	2	4-4-06	Lumpectomy	2
GSE20271	GSM508101	GPL96	66	11-25-05	2	P	90	2.4	2	P	Mixed; Ductal and Lobular	RD	0/23	1	P	70	0	2	Paclitaxel x(12 )  + FEC x(4 )	W	2	5-6-06	Lumpectomy	2
GSE20271	GSM508102	GPL96	47	4-11-05	2	P	75	ND	3	P	Infiltrating Ductal Carcinoma	RD	1/13	1.9	P	25	1	2	Paclitaxel x(12 )  + FEC x(4 )	W	2	5-15-06	Lumpectomy	2
GSE20271	GSM508103	GPL96	46	11-4-06	1	N	0	ND	0	N	Infiltrating Ductal Carcinoma	RD	2/23	2.3	N	0	0	2	Paclitaxel x(12 )  + FEC x(4 )	W	2	10-17-06	Lumpectomy	2
GSE20271	GSM508104	GPL96	46	8-3-06	3	N	0	1.5	2	N	Infiltrating Ductal Carcinoma	pCR	0/20	0	N	0	0	2	Paclitaxel x(12 )  + FEC x(4 )	W	2	4-9-06	Mastectomy	2
GSE20271	GSM508105	GPL96	56	2-27-06	NA	P	70	ND	0	N	Infiltrating Ductal Carcinoma	pCR	0/14	0	N	0	1	4	Paclitaxel x(12 )  + FEC x(3 )	W	2	8-28-06	Mastectomy	2
GSE20271	GSM508106	GPL96	71	10-3-06	3	N	0	0	2	N	Infiltrating Ductal Carcinoma	RD	3/25	0.26	N	0	1	2	Paclitaxel x(12 )  + FEC x(4 )	W	2	4-9-06	Mastectomy	2
GSE20271	GSM508107	GPL96	61	11-14-05	2	P	100	ND	2	N	Infiltrating Ductal Carcinoma	RD	0/17	1	P	90	0	2	Paclitaxel x(12 )  + FEC x( 4)	W	2	4-7-06	Mastectomy	2
GSE20271	GSM508108	GPL96	66	10-14-05	1	P	70	ND	0	N	Infiltrating Ductal Carcinoma	RD	2/18	1	P	30	1	1	Paclitaxel x(12)  + FEC x(3 )	W	2	4-20-06	Mastectomy	2
GSE20271	GSM508109	GPL96	45	11-4-06	1	P	15	1	3	P	Infiltrating Ductal Carcinoma	RD	0/20	1	P	100	0	2	Paclitaxel x(12 )  + FEC x(4 )	W	2	10-16-06	Mastectomy	2
GSE20271	GSM508110	GPL96	42	9-23-05	1	P	90	1	1	N	Inflitrating Lobular Carcinoma	RD	2/16	1.5	P	70	0	3	Paclitaxel x(12 )  + FEC x(4 )	W	2	3-21-06	Mastectomy	2
GSE20271	GSM508111	GPL96	68	5-8-05	3	N	0	ND	2	N	Infiltrating Ductal Carcinoma	RD	0/18	2.9	N	0	0	3	Paclitaxel x(12 )  + FEC x( 4)	W	2	9-12-05	Mastectomy	2
GSE20271	GSM508112	GPL96	45	1-3-06	3	P	68	ND	3	P	Infiltrating Ductal Carcinoma	RD	8/14	7.2	P	50	1	3	Paclitaxel x(12 )  + FEC x(4 )	W	2	8-30-06	Mastectomy	2
GSE20271	GSM508113	GPL96	31	10-17-05	3	N	0	ND	0	N	Infiltrating Ductal Carcinoma	RD	2/15	12	N	0	0	4	Paclitaxel x(12 )  + FEC x( 0)	W	2	1-31-06	Mastectomy	2
GSE20271	GSM508114	GPL96	46	7-20-04	3	N	0	6	3	P	IDC	pCR	0/10	0	N	0	2	3	Taxol x 12 FEC x 4	W	2	2-18-05	MRM	2
GSE20271	GSM508115	GPL96	71	12-12-03	2	N	0	9.26	3	P	IDC	pCR	0/17	0	N	0	1	1	Taxol x 12 FAC x 4	H	2	7-8-04	MRM	2
GSE20271	GSM508116	GPL96	50	10-4-04	3	N	1	1.04	NA	N	IDC	pCR	0/20	0	N	1	2	4	Taxol x 11( Pt missed the first D/T shingles),  FAC x 4	W	2	5-6-05	MRM	2
GSE20271	GSM508117	GPL96	57	4-15-05	3	P	100	1.02	1	N	IDC	RD	2/30	0	P	100	2	1	Taxol x 12 FAC x 6	W	2	12-14-05	MRM	2
GSE20271	GSM508118	GPL96	42	12-19-03	3	P	50	1.09	NA	N	IDC	RD	0/18	0.2	P	10	1	3	Taxol x 6 (d/t P.D)   FAC x 4	W	2	5-26-04	MRM	2
GSE20271	GSM508119	GPL96	68	5-4-04	2	P	10	NA	0	N	IDC	RD	5/9	0.7	P	90	3	0	Taxol x 12 FEC x 4	B	2	1-5-05	MRM	2
GSE20271	GSM508120	GPL96	71	10-15-04	3	P	30	NA	1	N	IDC	RD	2/10	1	N	NA	1	4	Taxol x 12 FAC x 4	H	2	5-12-05	MRM	2
GSE20271	GSM508121	GPL96	47	11-29-04	2	P	50	NA	NA	N	IDC	RD	3/21	1	P	80	1	4	Taxol x 12 FAC x 4	H	2	7-5-05	MRM	2
GSE20271	GSM508122	GPL96	73	7-21-04	2	P	100	NA	NA	N	IDC	RD	8/21	1	N	NA	1	4	Taxol x 12 FAC x 4	H	2	2-21-05	MRM	2
GSE20271	GSM508123	GPL96	40	11-4-03	3	P	50	NA	0	N	IDC	RD	9/22	1.6	P	50	1	1	FAC x 3 (d/t P.D) Taxol x 12	H	1	5-20-04	MRM	2
GSE20271	GSM508124	GPL96	49	11-20-03	2	P	90	0.86	2	N	IDC	RD	6/18	1.7	P	90	3	2	Taxol x 12 FAC x 4	A	2	8-16-04	MRM	2
GSE20271	GSM508125	GPL96	42	2-24-03	1	P	90	1.02	NA	N	ILC	RD	11/18	1.9	P	90	1	2	Taxol x 12 FAC x 4	W	2	9-13-04	MRM	2
GSE20271	GSM508126	GPL96	65	3-30-04	2	P	100	2.67	2	P	IDC	RD	1/12	2	P	60	1	1	FEC x 3 ( d/t N.C)Taxol x 12	W	1	10-22-04	MRM	2
GSE20271	GSM508127	GPL96	65	1-5-05	3	P	95	NA	NA	N	IDC	RD	2/25	2	P	70	2	2	Taxol x 12 FAC x 4	H	2	8-1-05	MRM	2
GSE20271	GSM508128	GPL96	47	6-27-00	2	P	90	1.27	2	N	IDC	RD	1/31	2.2	P	10	1	3	Taxol x 12 FAC x 4	B	2	2-12-01	MRM	2
GSE20271	GSM508129	GPL96	36	10-8-03	2	P	100	1.02	NA	N	IDC/ILC	RD	3/20	3	P	100	1	2	Taxol x 7 (d/t N.C) FAC x 4    (Multifocal,  Declined hormonal therapy and XRT)	W	2	3-31-04	MRM	2
GSE20271	GSM508130	GPL96	40	4-19-04	2	P	90	1	1	N	IDC	RD	3/24	3	P	90	1	2	Taxol x 12 FAC x 4	W	2	12-21-04	MRM	2
GSE20271	GSM508131	GPL96	53	1-29-04	3	N	0	1.35	1	N	IDC	RD	1/15	3.3	N	0	0	2	Adriamycin x 6 Cyclophosphamide x 6 Taxol x 12	H	1	11-8-04	MRM	2
GSE20271	GSM508132	GPL96	65	10-20-05	3	N	0	0.93	2	N	IDC	RD	1/38	5	N	0	1	3	Taxol x 12 FAC x 4	W	2	5-4-06	MRM	2
GSE20271	GSM508133	GPL96	60	4-8-04	2	P	50	1.05	NA	N	ILC	RD	0/21	8	P	40	0	3	Taxol x 12 FEC x 4	H	2	10-29-04	MRM	2
GSE20271	GSM508134	GPL96	43	5-25-05	3	N	0	0	NA	N	IDC	RD	0/15	12.5	N	0	3	4	Taxol x 8 (d/t P.D) FEC x 6 (P.D) XRT+ Xeloda	B	2	3-31-06	MRM	2
GSE20271	GSM508135	GPL96	37	2-2-05	3	P	40	NA	3	P	IDC	RD	21/21	NA	N	NA	2	4	Taxol x 12 FAC x 4	H	2	9-26-05	MRM	2
GSE20271	GSM508136	GPL96	48	9-23-05	2	P	10	NA	NA	N	IDC	RD	NA	residual cancer	N	NA	2	4	Taxol x 12 FAC x 4	H	2	6-22-06	MRM	2
GSE20271	GSM508137	GPL96	53	7-8-05	NA	N	NA	NA	NA	N	IDC	pCR	0/7	0	N	NA	0	4	Taxol x 12 FAC x 4	H	2	5-30-06	MRM/ALND	2
GSE20271	GSM508138	GPL96	58	12-16-05	NA	N	NA	NA	NA	N	IDC	pCR	0/13	0	N	NA	1	4	Taxol x 12 FAC x 4	H	2	7-11-06	MRM/ALND	2
GSE20271	GSM508139	GPL96	58	12-6-05	3	N	0	NA	0	N	IDC	RD	17/30	1.5	N	0	3	2	Taxol x 11 ( one dose missed & no repleced) FEC x 4	W	2	8-1-06	MRM/ALND	2
GSE20271	GSM508140	GPL96	66	6-20-05	2	P	80	NA	NA	N	IDC	RD	10/13	NA	P	10	2	2	Taxol x 12 FAC x 4	H	2	6-13-06	MRM/ALND	2
GSE20271	GSM508141	GPL96	53	7-3-04	NA	N	0	NA	0	N	IDC	RD	1/14	NA	N	0	2	4	Taxol x 12    FEC x 4	H	2	5-11-05	MRM/ALND	2
GSE20271	GSM508142	GPL96	39	8-17-05	2	P	80	NA	NA	N	IDC	RD	11/15	NA	P	50	1	2	Taxol x 12 FAC x 4	H	2	6-17-06	MRM/ALND	2
GSE20271	GSM508143	GPL96	48	2-24-06	2	P	80	NA	NA	N	IDC	RD	5/16	NA	P	60	1	4	Taxol x 12 FAC x 4	H	2	10-14-06	MRM/ALND	2
GSE20271	GSM508144	GPL96	59	10-28-05	2	N	NA	NA	NA	N	IDC	RD	14/16	NA	N	NA	3	4	Taxol x 12 FAC x 4	H	2	5-27-06	MRM/ALND	2
GSE20271	GSM508145	GPL96	42	9-23-05	NA	P	95	NA	2	N	IDC	RD	1/21	NA	P	80	2	4	Taxol x 12 FAC x 4	H	2	5-9-06	MRM/ALND	2
GSE20271	GSM508146	GPL96	63	12-19-05	NA	N	NA	NA	NA	N	IDC	RD	12/16	NA	N	NA	1	2	Taxol x 12 FAC x 4	H	2	8-1-06	MRM/ALND	2
GSE20271	GSM508147	GPL96	40	9-23-05	3	P	70	NA	NA	N	IDC	RD	0/10	residual cancer	P	80	1	3	Taxol x 12 FAC x 4	H	2	5-9-06	MRM/ALND	2
GSE20271	GSM508148	GPL96	50	4-26-06	3	N	NA	NA	3	P	IDC	RD	0/24	residual cancer	N	NA	1	3	Taxol x 12 FAC x 4	H	2	2-1-07	MRM/ALND	2
GSE20271	GSM508149	GPL96	46	10-15-04	3	P	75	NA	0	N	IDC	pCR	0/2	0	P	75	0	2	Taxol  x 12  FAC   x 4	H	2	6-9-05	MRM/LNB	2
GSE20271	GSM508150	GPL96	45	6-16-05	NA	P	NA	NA	0	N	ILC	pCR	0/26	0	N	0	0	2	Taxol x 12   FEC x 4	H	2	1-21-06	NA	2
GSE20271	GSM508151	GPL96	64	8-8-05	NA	N	0	NA	3	P	IDC	pCR	0/6	0	N	0	0	2	Taxol x12   FEC x 4	H	2	4-19-06	NA	2
GSE20271	GSM508152	GPL96	49	9-6-05	3	N	0	NA	0	N	IDC	pCR	0/14	0	N	0	0	3	Taxol x 12 FEC x 4	H	2	5-12-06	NA	2
GSE20271	GSM508153	GPL96	37	8-30-04	NA	N	0	NA	0	N	IDC	RD	3/6	NA	N	0	2	3	Taxol x 12    FEC x 4	H	2	6-10-05	NA	2
GSE20271	GSM508154	GPL96	61	8-16-04	3	N	0	NA	0	N	IDC	RD	6/10	NA	N	0	0	2	Taxol x 12    FEC x 4	H	2	7-28-05	NA	2
GSE20271	GSM508155	GPL96	61	5-5-05	3	P	NA	NA	1	N	IDC	RD	3/15	NA	P	NA	2	2	Taxol x 12    FEC x 4	H	2	12-6-05	NA	2
GSE20271	GSM508156	GPL96	46	3-1-05	3	N	0	NA	2	P	IDC	RD	18/20	NA	N	0	2	4	Taxol x 12    FEC x 4	H	2	10-4-05	NA	2
GSE20271	GSM508157	GPL96	65	9-19-05	NA	N	0	NA	0	N	IDC	RD	0/15	residual cancer	N	0	0	4	Taxol x 12   FEC x 4	H	2	4-12-06	NA	2
GSE20271	GSM508158	GPL96	44	12-30-05	NA	N	NA	NA	NA	N	IDC	RD	ND	ND	N	NA	2	4	Taxol x 12 FAC x 4	H	2	ND	ND	2
GSE20271	GSM508159	GPL96	59	10-20-04	2	P	31	NA	2	N	IDC/IBC	RD	ND	ND	N	4	2	4	Taxol  x 12   FAC x  3 (D/T P.D)	W	2	ND	ND	2
GSE20271	GSM508160	GPL96	44	8-26-05	NA	N	NA	NA	NA	P	IDC	RD	ND	ND	N	NA	1	4	Taxol x 8  (D/T progression)	H	2	ND	ND	2
GSE20271	GSM508161	GPL96	29	1-25-06	NA	N	NA	NA	NA	N	IDC	RD	ND	ND	N	NA	1	4	Taxol x 5   (Off protocol D/T progression)	H	2	ND	ND for PD	2
GSE20271	GSM508162	GPL96	55	8-19-05	NA	N	NA	NA	NA	N	IDC	RD	ND	ND	N	NA	1	3	Taxol x 12 FAC x 4	H	2	ND	ND for PD and brain mets	2
GSE20271	GSM508163	GPL96	58	1-28-05	3	N	NA	NA	NA	N	IDC	RD	ND	ND	N	NA	2	4	Taxol x 12 FAC x 4  (Progressed on Neoadjuvant Chemotherapy. Moved on to XRT. No surgery)	H	2	ND	ND for PD and reccurrence	2
GSE20271	GSM508164	GPL96	48	3-20-06	3	P	25	ND	3	P	Infiltrating Ductal Carcinoma	pCR	0/10	0	P	40	1	3	Paclitaxel x(12 )  + FEC x(4 )	W	2	9-19-06	Quadrantectomy	2
GSE20271	GSM508165	GPL96	45	7-29-05	3	N	0	ND	3	P	Infiltrating Ductal Carcinoma	pCR	0/14	0	N	0	0	2	Paclitaxel x(12 )  + FEC x(4 )	W	2	2-27-06	Quadrantectomy	2
GSE20271	GSM508166	GPL96	44	3-14-06	1	N	0	ND	0	N	Infiltrating Ductal Carcinoma	RD	4/6	1.3	P	25-50	1	3	Paclitaxel x(12 )  + FEC x(4 )	W	2	6-9-06	Quadrantectomy	2
GSE20271	GSM508167	GPL96	61	9-23-05	1	P	90	ND	0	N	Inflitrating Lobular Carcinoma	RD	1/11	1.5	P	60	0	2	Paclitaxel x(12 )  + FEC x(4 )	W	2	7-3-06	Quadrantectomy	2
GSE20271	GSM508168	GPL96	67	9-9-05	2	P	95	ND	2	N	Infiltrating Ductal Carcinoma	RD	0/20	2.8	P	90	0	2	Paclitaxel x(12 )  + FEC x(4 )	W	2	6-3-06	Quadrantectomy	2
GSE20271	GSM508169	GPL96	64	2-17-06	3	P	25-50	ND	0	N	Infiltrating Ductal Carcinoma	RD	0/11	1.3	P	25	1	3	Paclitaxel x( 12)  + FEC x(4 )	W	2	9-13-06	Quadrantectomy both breasts	2
GSE20271	GSM508170	GPL96	53	10-31-03	2	N	0	1.3	2	N	IDC	pCR	0/21	0	N	0	1	2	Taxol x 12 FEC x 4	W	2	6-16-04	SM	2
GSE20271	GSM508171	GPL96	55	3-15-04	3	N	0	10.36	NA	P	IDC	pCR	0/13	0	N	0	3	2	Taxol x 12 FAC x 4	B	2	11-23-04	SM	2
GSE20271	GSM508172	GPL96	44	6-10-04	2	P	95	1.63	NA	N	IDC	RD	0/18	2.5	N	0	0	2	Taxol x 12 FEC x 4	B	2	3-7-05	SM	2
GSE20271	GSM508173	GPL96	59	12-14-04	3	N	0	0.96	1	N	IDC	pCR	0/20	0	N	0	1	2	FAC x 4(d/t N.C) Taxol x 6 (d/t severe Fatigue) (FAC resistance & pCR at the end)	B	1	6-16-05	SM/ALND	2
GSE20271	GSM508174	GPL96	49	7-21-05	3	N	0	1.12	NA	N	IDC	pCR	0/20	0	N	0	1	2	Taxol x 12 FEC x 4	W	2	4-12-06	SM/ALND	2
GSE20271	GSM508175	GPL96	54	11-20-03	2	P	100	0.88	NA	N	IDC	RD	2/20	0	N	4.9	1	4	FAC x 6 Taxol x 12	H	1	11-5-04	SM/ALND	2
GSE20271	GSM508176	GPL96	58	2-8-05	3	N	0	1.08	2	N	IDC	RD	1/12	2.3	N	0	1	2	Taxol x 12 FAC x 4	B	2	9-1-05	SM/ALND	2
GSE20271	GSM508177	GPL96	35	1-26-05	2	P	100	NA	0	N	IDC	RD	6/7	2.5	P	100	1	1	Taxol x 12 FAC x 4	H	2	8-10-05	SM/ALND	2
GSE20271	GSM508178	GPL96	51	5-22-06	NA	N	NA	NA	NA	N	IDC	RD	3/10	NA	N	NA	2	4	Taxol x 12 FAC x  4	H	2	12-21-06	SM/ALND	2
GSE20271	GSM508179	GPL96	39	10-26-05	3	N	0	NA	0	N	IDC	pCR	0/2	0	N	0	1	3	Taxol  x  12  FAC x  4	B	2	6-30-06	SM/LNB	2
GSE20271	GSM508180	GPL96	26	10-23-03	2	P	95	0.92	NA	N	IDC	RD	0/4	0.8	P	95	0	2	Taxol x 12 FAC x 4	W	1	4-29-04	SM/LNB	2
GSE20271	GSM508181	GPL96	38	5-18-05	3	P	100	NA	0	N	IDC	RD	0/1	1	P	40	0	3	Taxol   x  12  FAC  x  4	H	2	3-3-06	SM/LNB	2
GSE20271	GSM508182	GPL96	36	3-15-06	3	N	0	1.32	2	N	IDC	RD	0/2	1.5	N	9	0	2	Taxol x 12 FEC x 4	W	2	11-17-06	SM/LNB	2
GSE20271	GSM508183	GPL96	48	10-20-05	2	N	0	0.96	1	N	IDC	RD	0/5	3	P	10	0	1	Taxol x 12 FAC x 4	H	2	6-8-06	SM/LNB	2
GSE20271	GSM508184	GPL96	73	1-26-06	1	P	95	0.86	1	N	IDC	RD	14/18	4	P	90	1	2	Taxol x 12 FEC x4	W	2	8-15-06	SM/LNB	2
GSE20271	GSM508185	GPL96	53	2-22-06	2	P	100	NA	0	N	ILC/IDC	RD	0/1	4.5	P	50	1	2	Taxol x 12 FEC x 4	W	2	12-20-06	SM/LNB	2
GSE20271	GSM508186	GPL96	53	12-21-05	1	P	90	0	NA	N	IDC	RD	2/9	2.8	P	30	0	2	Taxol x 12  FEC x4	W	2	8-15-06	TM/ALND	2
GSE20271	GSM508187	GPL96	56	5-26-06	1	P	10	NA	0	N	ILC	RD	1/14	8	P	80	0	3	Taxol x 12 FEC x 4	B	2	12-19-06	TM/ALND	2
GSE20271	GSM508188	GPL96	50	10-25-04	2	N	0	1.6	NA	N	IDC/ILC	RD	4/18	10	N	0	0	2	FEC x 3 (N.C) Taxol x 12	W	1	5-27-05	TM/ALND	2
GSE20271	GSM508189	GPL96	49	6-16-06	2	P	100	1.18	NA	N	IDC	RD	1/18	2	P	95	0	4	Taxol x 12 FAC x 4	W	2	2-2-07	TM/LNB	2
